-transparent.png){kind=logo}
The anti-human, high molecular weight-melanoma associated antigen (HMW-MAA) MoAb 225.28S was chelated with 111In and then tested for its in vitro reactivity with cultured human melanoma cells and for its biodistribution in human melanoma bearing nude mice. In vitro studies showed that the radiolabeled antibody reacted specifically with cultured melanoma cells. However, binding of DTPA to the monoclonal antibody reduced its titer with cultured melanoma cells from 1:1024 to 1:512. Further labeling of the DTPA-antibody conjugate with 111In caused an additional reduction of its titer to 1:128. Injection of the radiolabeled monoclonal antibody into nude mice resulted in the accumulation of significantly (p less than 0.001) higher radioactivity in melanoma tissue than in nude mice injected with either [111In] chloride or 111In-labeled antibody to human acid phosphatase. The specificity of the distribution of the radiolabeled antibody in nude mice also was indicated by its poor localization in lesions other than melanoma (e.g., human prostate carcinoma and chronic abscess). The localization of antibody in liver and kidney was also high, although lower than that achieved in tumor. These results indicate that 111In-labeled monoclonal antibodies to human tumor associated antigens may be useful for localizing malignant lesions. However, there is a need to improve labeling and/or purification of antibody in order to decrease renal and hepatic activity.
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
March 1988,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
January 1987,
NCI monographs : a publication of the National Cancer Institute,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
December 1987,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
October 1986,
Investigative radiology,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
January 1987,
NCI monographs : a publication of the National Cancer Institute,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
January 1989,
Cancer immunology, immunotherapy : CII,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
April 1996,
Nuclear medicine and biology,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
September 1991,
Cancer research,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
January 1988,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
R A Fawwaz, and
T S Wang, and
A Estabrook, and
J M Rosen, and
M A Hardy, and
P O Alderson, and
S C Srivastava, and
P Richards, and
S Ferrone
January 1987,
NCI monographs : a publication of the National Cancer Institute,
